LCI - Lannett Company, Inc.
| Previous Close | 15.85 |
| Open | 15.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 15.65 - 16.40 |
| 52 Week Range | 14.40 - 30.35 |
| Volume | 478,157 |
| Avg. Volume | 711,285 |
| Market Cap | 603.605M |
| Beta | 1.85 |
| PE Ratio (TTM) | 12.45 |
| EPS (TTM) | 1.28 |
| Earnings Date | Apr 30, 2018 - May 4, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.86 |
- PR Newswire•5 days ago
Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer
--Company Re-aligns Management Responsibilities-- PHILADELPHIA , April 20, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Maureen M. Cavanaugh to the newly created ...
- Zacks•12 days ago
Zacks Value Investor Highlights: Lannett, Emerge Energy, Roadrunner, GameStop and Micron
Zacks Value Investor Highlights: Lannett, Emerge Energy, Roadrunner, GameStop and Micron
- Simply Wall St.•13 days ago
Why Lannett Company Inc (NYSE:LCI) May Not Be As Efficient As Its Industry
Lannett Company Inc’s (NYSE:LCI) most recent return on equity was a substandard 8.09% relative to its industry performance of 10.88% over the past year. Though LCI’s recent performance is underwhelming,Read More...
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of LCI presentation 6-Mar-17 7:50pm GMT
Lannett Company Inc at Raymond James Institutional Investors Conference
- PR Newswire•last month
Lannett Strengthens, Augments Management Team
PHILADELPHIA, March 23, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced the appointments of Grant Brock as vice president operations and Alicia Evolga as vice president of marketing. Grant joined the company last month and Alicia begins April 2, 2018.
- Zacks•last month
Is Lannett Company (LCI) a Great Stock for Value Investors?
Is Lannett Company (LCI) a great pick from the value investor's perspective right now? Read on to know more.
- American City Business Journals•last month
Hat trick: Lannett enters into 3 product agreements
Lannett Co. Inc. said Monday, in a move to create new revenues streams, it has entered into separate agreements with three strategic alliance partners. Initially, the agreements cover one product from each partner: Diclofenac ER, a nonsteroidal anti-inflammatory drug used to treat to treat mild to moderate pain or signs and symptoms of osteoarthritis or rheumatoid arthritis, and Fluvastatin ER, a cholesterol-lowering medication. Crew said Lannett expects to launch Diclofenac ER within the next few months.
- PR Newswire•last month
Lannett Adds New Revenue Streams, Announces Agreements With Three Strategic Alliance Partners
PHILADELPHIA, March 12, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into separate agreements with three strategic alliance partners. Under two of the agreements, Lannett will serve as the exclusive U.S. distributor for certain off-patent products manufactured by the partners. Initially, the agreements cover one product from each partner, Diclofenac ER and Fluvastatin ER. Under the third agreement, Lannett will provide five of its currently marketed products to Pharmaceutical Associates, Inc. (PAI) for repackaging into unit dose cups and distribution into the managed care and hospital markets. For all the above transactions, Lannett will receive a percentage of the net profits. Other financial terms were not disclosed. For the 12 months ended January 2018, total U.S. generic sales of Diclofenac ER were approximately $8.7 million, and total U.S. sales of Fluvastatin ER were approximately $15.5 million, according to IMS. Currently, Diclofenac ER has one generic competitor and Fluvastatin ER has three. Diclofenac ER is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild-to-moderate pain and helps to relieve symptoms of arthritis and Fluvastatin ER is a cholesterol-lowering drug.
- ACCESSWIRE•2 months ago
Free Post Earnings Research Report: Lannett's Quarterly Earnings Advanced 15.22%
Stock Monitor: Pacira Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 9, 2018 / Active-Investors.com has just released a free earnings report on Lannett Co., Inc. (NYSE: LCI ). If you want ...
- PR Newswire•2 months ago
Lannett To Participate At Three Investor Conferences In March
PHILADELPHIA , Feb. 27, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at three investor conferences in March. The schedule and details are as follows: ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of LCI earnings conference call or presentation 7-Feb-18 9:30pm GMT
Q2 2018 Lannett Company Inc Earnings Call
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma — Discovering Underlying Factors of Influence
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, ...
- Motley Fool•2 months ago
Why Lannett Company, Inc. Is Falling Today
Shares tumbled after the generic-drug maker shared quarterly results that came up short of expectations.
- Associated Press•3 months ago
Lannett beats 2Q profit forecasts
On a per-share basis, the Philadelphia-based company said it had net income of 37 cents. Earnings, adjusted for non-recurring costs and amortization costs, were $1.06 per share. The results exceeded Wall ...
- PR Newswire•3 months ago
Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings
--Adjusted EPS Higher Than Expected; Full-Year Adjusted Profitability Expected to Improve-- PHILADELPHIA , Feb. 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results ...
- PR Newswire•3 months ago
Lannett Voluntarily Pays Down $25 Million Of Term Loans
PHILADELPHIA , Feb. 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $25 million payment against its Term Loans. "Paying down our debt ...
- PR Newswire•3 months ago
Lannett Enters Into Consulting Agreement With Former CEO, Arthur Bedrosian
Under the agreement, Bedrosian will work with the company on several important projects primarily involving existing and new partnering efforts to expand and diversify opportunities, including but not limited to spearheading the effort to transition and strengthen the company's existing contractual relationships with its key partners. Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
- PR Newswire•3 months ago
Lannett To Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 7
PHILADELPHIA , Jan. 31, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 second quarter on Wednesday, February 7, 2018 , ...
- Simply Wall St.•3 months ago
What Does Lannett Company Inc’s (NYSE:LCI) Share Price Indicate?
Lannett Company Inc (NYSE:LCI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...
- PR Newswire•3 months ago
Lannett Names Timothy C. Crew To Board Of Directors
PHILADELPHIA , Jan. 18, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that Timothy C. Crew , the company's recently appointed chief executive officer (CEO), has been added to the ...
- Investor's Business Daily•3 months ago
Stocks Showing Improved Relative Strength: Lannett
Lannett shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
- Business Wire•4 months ago
Haeggquist & Eck Investigates Breach of Fiduciary Duties by Lannett Officers and Directors Related to Criminal Investigation into Potential Price Collusion
Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc. breached their fiduciary duties to the Company and its shareholders.
- Investor's Business Daily•4 months ago
Stocks Generating Improved Relative Strength: Lannett
A Relative Strength Rating upgrade for Lannett shows improving technical performance. Will it continue?
- Capital Cube•4 months ago
ETFs with exposure to Lannett Co., Inc. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lannett Co., Inc. Here are 5 ETFs with the largest exposure to LCI-US. Comparing the performance and risk of Lannett Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
